IMNM files 8-K for Q3 2025 results; Exhibit 99.1 furnished

Rhea-AI Filing Summary

Immunome (IMNM) filed an 8-K announcing third-quarter results. The company reported its financial results for the quarter ended September 30, 2025 and provided a business update via a press release furnished as Exhibit 99.1.

The disclosure was made under Item 2.02 (Results of Operations and Financial Condition). The press release is furnished, not filed, which means it is not subject to Section 18 liabilities and is not incorporated into other SEC filings unless expressly referenced. The filing also lists the Inline XBRL cover page as Exhibit 104.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000147201200014720122025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

November 6, 2025

Immunome, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39580		77-0694340
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

18702 N. Creek Parkway, Suite 100 Bothell, WA		98011
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (425) 939-7410

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		IMNM		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Immunome, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2025 and provided a business update in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit Number	Description
99.1		Press Release dated November 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2025	Immunome, Inc.
	By:	/s/ Max Rosett
	Name:	Max Rosett
	Title:	Chief Financial Officer

FAQ

What did Immunome (IMNM) announce in this 8-K?

Immunome announced financial results for the third quarter ended September 30, 2025 and provided a business update via a press release (Exhibit 99.1).

Which item of the 8-K covers Immunome’s update?

Item 2.02 (Results of Operations and Financial Condition).

Where can I find the detailed Q3 2025 results for IMNM?

Details are in the press release furnished as Exhibit 99.1 to the 8-K.

Is the press release considered filed with the SEC?

No. It is furnished, not filed, and not subject to Section 18 liabilities or automatically incorporated into other filings.

What period do the results cover for IMNM?

The quarter ended September 30, 2025.

Which exchange lists Immunome’s common stock?

The Nasdaq Capital Market, under the ticker IMNM.

What exhibits accompanied the 8-K?

Exhibit 99.1 (press release dated November 6, 2025) and Exhibit 104 (Inline XBRL cover page).